Navigation Links
Amicus Therapeutics Announces Second Quarter 2009 Financial Results Release Date
Date:7/29/2009

CRANBURY, N.J., July 29 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) will announce second quarter 2009 financial results after the regular close of markets on Wednesday, August 5, 2009. The results announcement will be followed by a live conference call and webcast that afternoon at 5 p.m. EDT.

Interested participants and investors may access the conference call at 5 p.m. EDT by dialing 877-591-4949 (U.S./Canada) or 719-325-4889 (international). A telephonic replay of the call will be available for seven days beginning at 8 p.m. EDT. Access numbers for this replay are 888-203-1112 (U.S./Canada) and 719-457-0820 (international); participant code 4035217.

An audio webcast can also be accessed via the investor section of the Amicus Therapeutics Web site at www.amicustherapeutics.com under Investors: Events and Presentations. Web participants are encouraged to go to the Web site 15 minutes prior to the start of the call to register, download and install any necessary software. After the live webcast, an audio webcast replay will remain available in the Investors section of the Amicus Therapeutics Web site for 30 days.

Amicus' press releases are available at www.amicustherapeutics.com.

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs.

FOLD -G


'/>"/>
SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Amicus Therapeutics to Present at the Bank of America and Merrill Lynch 2009 Health Care Conference on May 13, 2009
2. Amicus Therapeutics Announces First Quarter 2009 Financial Results Release Date
3. Amicus Therapeutics to Present at the 16th Annual Future Leaders in the Biotech Industry Conference
4. Amicus Therapeutics Presents Positive Results From Phase 2 Extension Study of Amigal(TM) for Fabry Disease at ACMG 2009 Annual Meeting
5. Amicus Therapeutics to Present at the Cowen and Company 29th Annual Healthcare Conference on March 17, 2009
6. Amicus Therapeutics Announces Change to Board of Directors
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2008 Financial Results
8. Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date
9. Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors
10. Amicus Therapeutics to Present at Lazard Capital Markets Healthcare Conference
11. Amicus Therapeutics Announces Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... June 27, 2016  Global demand for enzymes ... through 2020 to $7.2 billion.  This market includes ... cleaning products, biofuel production, animal feed, and other ... and biocatalysts). Food and beverages will remain the ... increasing consumption of products containing enzymes in developing ...
(Date:6/27/2016)... ... June 27, 2016 , ... Cancer experts from Austria, ... could be a new and helpful biomarker for malignant pleural mesothelioma. Surviving Mesothelioma ... read it now. , Biomarkers are components in the blood, tissue or ...
(Date:6/27/2016)... , ... June 27, 2016 , ... ... for Amgen, will join the faculty of the University of North Carolina ... professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus on the ...
(Date:6/24/2016)... discussions on a range of subjects including policies, debt and ... Poloz. Speaking at a lecture to the Canadian ... to the country,s inflation target, which is set by both ... "In certain areas there needs to be ... why not sit down and address strategy together?" ...
Breaking Biology Technology:
(Date:5/16/2016)... NEW YORK , May 16, 2016   ... authentication solutions, today announced the opening of an IoT ... to strengthen and expand the development of embedded ... provides an unprecedented level of convenience and security with ... to authenticate one,s identity aside from DNA. EyeLock,s platform ...
(Date:4/28/2016)... , April 28, 2016 First quarter 2016: ... up 966% compared with the first quarter of 2015 ... SEK 589.1 M (loss: 18.8) and the operating margin was 40% ... 0.32) Cash flow from operations was SEK 249.9 M ... revenue guidance is unchanged, SEK 7,000-8,500 M. The operating ...
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
Breaking Biology News(10 mins):